MediClin AG (XTER:MED) Change In Receivables: €0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:MED MediClin AG XTER:MED
75 GF Score
Price €5.45
GF Value €3.20
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is MediClin AG Change In Receivables?

MediClin AG XTER:MED 75 Change In Receivables is €0.0 Mil as of Jun. 2026. GuruFocus rates XTER:MED with a GF Score™ of 75/100 and a GF Value™ of €3.20 (Significantly Overvalued). The stock has 6 warning signs investors should review.

MediClin AG's change in receivables for the quarter that ended in Jun. 2026 was €0.0 Mil. It means MediClin AG's Accounts Receivable stayed the same from Mar. 2026 to Jun. 2026 .

MediClin AG's change in receivables for the fiscal year that ended in Dec. 2025 was €0.0 Mil. It means MediClin AG's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

MediClin AG's Accounts Receivable for the quarter that ended in Jun. 2026 was €92.3 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. MediClin AG's Days Sales Outstanding for the three months ended in Jun. 2026 was 42.20.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. MediClin AG's liquidation value for the three months ended in Jun. 2026 was €-353.0 Mil.

MediClin AG  (XTER:MED) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

MediClin AG's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=92.25/199.477*91
=42.20

2. In Ben Graham's calculation of liquidation value, MediClin AG's accounts receivable are only considered to be worth 75% of book value:

MediClin AG's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=159.13-583.984+0.75 * 92.25+0.5 * 5.429
=-353.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediClin AG Change In Receivables Related Terms

MediClin AG Change In Receivables Historical Data

* Premium members only.

The historical data trend for MediClin AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediClin AG Change In Receivables Chart

MediClin AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MediClin AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XTER:MED
75GF Score
MediClin AG XTER:MED
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MediClin AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €0.0 Mil mean?
MediClin AG (XTER:MED) has a Change In Receivables of €0.0 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for MediClin AG and its competitors.
Is MediClin AG's Change In Receivables too high?
MediClin AG's current Change In Receivables is €0.0 Mil. Overall, MediClin AG has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediClin AG's Change In Receivables compare to HCA and THC?
MediClin AG's Change In Receivables of €0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Healthcare Providers & Services company?
A good Change In Receivables depends on the Healthcare Providers & Services industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for MediClin AG and its competitors. MediClin AG's current Change In Receivables is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediClin AG stock overvalued right now?
Based on GuruFocus' analysis, MediClin AG (XTER:MED) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.20, compared to a current price of €5.45 — trading 70.3% above its estimated fair value. The current Change In Receivables is €0.0 Mil. MediClin AG's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For MediClin AG (XTER:MED), the current Change In Receivables is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MediClin AG (XTER:MED) Overvalued in 2026?

Based on GuruFocus' analysis, MediClin AG stock appears to be overvalued. The current stock price of €5.45 is trading 70.3% above its estimated GF Value™ of €3.20. GuruFocus considers MediClin AG to be Significantly Overvalued.

Key valuation signals for XTER:MED:

  • Change In Receivables: €0.0 Mil
  • GF Value™: €3.20 vs. price of €5.45 (70.3% above fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the XTER:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MediClin AG Business Description

Other Exchanges 0NDG:UK
Address Okenstrasse 27, Offenburg, BW, DEU, 77652
MediClin AG operates hospitals and other medical care centers. The company's reportable operating segments are the Post-acute, Acute, Nursing care, and Service segments. A majority of its revenue is generated from the Post-acute segment, which offers services in the fields of follow-up rehabilitation treatment and curative treatment. Some of the post-acute hospitals also offer services in acute neurology and acute psychosomatics. The Acute segment encompasses medical offerings with a focus on neurology and neurological early rehabilitation as well as psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. The Nursing care segment offers full-time and part-time nursing care as well as daycare, and the Service segment consists of the central services.
75GF Score

Get the complete analysis for XTER:MED

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.45
Price
€3.20
GF Value